Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO is it bear time? Or do we go bull? | glenn1919 | investorshub | 09/23/2023 4:56:37 PM |
Price gaining | StocksNcash | investorshub | 09/23/2023 4:40:28 PM |
MomentumIts now last up | Pisd | investorshub | 09/23/2023 4:04:31 PM |
$OKYO Price trading last trade up | Boris the Spider | investorshub | 09/23/2023 2:53:03 PM |
$OKYO The gaining | Ryguy008 | investorshub | 09/23/2023 2:46:39 PM |
what do you make of this data? | Pisd | investorshub | 09/23/2023 2:06:51 PM |
Found an interesting article | mfayman | investorshub | 09/23/2023 1:12:35 PM |
$OKYO Do we have a winner?Turn around time? | mfayman | investorshub | 09/23/2023 1:10:41 PM |
$OKYO is it bear time? Or do we go bull? | Anita Dump | investorshub | 09/23/2023 11:43:02 AM |
Price trading | Pisd | investorshub | 09/23/2023 10:59:28 AM |
$OKYO Found an interesting article | ErnieBilco | investorshub | 09/23/2023 10:54:36 AM |
$OKYO MomentumIts trading | ErnieBilco | investorshub | 09/23/2023 9:40:03 AM |
MomentumIts now | Boris the Spider | investorshub | 09/23/2023 8:13:24 AM |
$OKYO Price gaining | Sirpeter | investorshub | 09/23/2023 7:49:52 AM |
$OKYO Price gaining | mfayman | investorshub | 09/23/2023 7:15:56 AM |
The gaining | mfayman | investorshub | 09/23/2023 6:25:38 AM |
The now last up | StocksNcash | investorshub | 09/23/2023 6:24:52 AM |
$OKYO MomentumIts trading | glenn1919 | investorshub | 09/23/2023 4:11:51 AM |
$OKYO Time for a bounce? | Count Crypto | investorshub | 09/23/2023 3:32:49 AM |
$OKYO Thoughts on where this is headed? | Pisd | investorshub | 09/23/2023 3:31:06 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...